A Health 4.0 Based Approach Towards the Management of Multiple Sclerosis

Multiple sclerosis is a chronic and variable disease in matters of symptoms, clinical course and outcome. The ultimate goal of currently used drugs and therapeutic strategies is the control of disease activity and the delay of the ongoing disability. During the last decades, a number of disease-modifying drugs (DMDs), all products of advanced biotechnology are being used. However, these DMDs are yet partially effective since the ongoing disability progression may hardly be prevented. There is growing evidence that these DMDs might be more effective if more accurate monitoring of the disease itself throughout a period of time might be available. In the new era of MS treatment and on the basis of our current knowledge about MS management, it became pretty clear that the overall therapeutic strategy should always be scheduled on strictly individualized basis. To this, MS patients should be encouraged to take control over their own disease and collaborate more effectively with their doctors. The advent of the IoT (Internet of Things) and 5G mobile technologies can support patients in this direction. Since a snapshot of the overall patient’s condition during a regular follow-up visit may not represent the every day reality of the patient, the advice given under these conditions may not be that effective. However, if hard data on the patient’s motoric and cognitive performance were available “theragnostics” might be much more effective and efficient and a typical flare-up of the condition might be recognized much earlier—or even anticipated. Health 4.0 is the translation of Industry 4.0 design principles into the health domain. Health 4.0 is based on the utilization of the Internet of Things (IoT) and the use of cyber-physical systems to connect the physical and the virtual world. The use of smart pharmaceuticals biosensors and cyber-physical systems in the management of MS could optimize the accuracy and allow for a precise mapping of symptoms over time which is an inevitable prerequisite for personalization of care. Ideally captured data would be processed in real time in order to flag problems up to the care team and on an individual basis anticipate motoric and/or cognitive deficits in an attempt to compensate for neurological deficits. 5G networks are expected to provide the infrastructure and ease in supporting various parameters recording on a real-time basis. Relevant clinical studies may further highlight the need of information communication technology in MS management, thus contributing to the overall improvement of patent’s quality of life (QoL). This is an absolute necessity for a variable, fluctuating and largely unpredictable disease such as MS.

[1]  Robert W Motl,et al.  Internet intervention for increasing physical activity in persons with multiple sclerosis , 2011, Multiple sclerosis.

[2]  Helga E de Vries,et al.  Mitochondrial dysfunction: a potential link between neuroinflammation and neurodegeneration? , 2010, Mitochondrion.

[3]  Wayne H. Wolf,et al.  Cyber-physical Systems , 2009, Computer.

[4]  P Michael Ho,et al.  Medication Adherence: Its Importance in Cardiovascular Outcomes , 2009, Circulation.

[5]  Christine Stadelmann,et al.  Wallerian Degeneration: A Major Component of Early Axonal Pathology in Multiple Sclerosis , 2010, Brain pathology.

[6]  Jennifer Smrtka,et al.  Loss of mobility and the patient burden of multiple sclerosis: expert opinion on relevance to daily clinical practice , 2016, Postgraduate medicine.

[7]  E. Deci,et al.  Facilitating health behaviour change and its maintenance: Interventions based on Self-Determination Theory , 2008 .

[8]  E. Deci,et al.  Self-determination theory and the facilitation of intrinsic motivation, social development, and well-being. , 2000, The American psychologist.

[9]  Mondher Toumi,et al.  The payer’s perspective: What is the burden of MS and how should the patient’s perspective be integrated in health technology assessment conducted for taking decisions on access to care and treatment? , 2016, Multiple sclerosis.

[10]  Michelle H Cameron,et al.  Measurement and treatment of imbalance and fall risk in multiple sclerosis using the international classification of functioning, disability and health model. , 2013, Physical medicine and rehabilitation clinics of North America.

[11]  J M Land,et al.  Nitric Oxide‐Mediated Mitochondrial Damage in the Brain: Mechanisms and Implications for Neurodegenerative Diseases , 1997, Journal of neurochemistry.

[12]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[13]  M. Filippo,et al.  Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[14]  P Lindgren,et al.  Costs and quality of life of patients with multiple sclerosis in Europe , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[15]  Thomas Nyffeler,et al.  Cognitive Impairment in Multiple Sclerosis: Clinical Manifestation, Neuroimaging Correlates, and Treatment , 2016, Seminars in Neurology.

[16]  David H. Miller,et al.  Gray matter atrophy is related to long‐term disability in multiple sclerosis , 2008, Annals of neurology.

[17]  L. Osterberg,et al.  Adherence to medication. , 2005, The New England journal of medicine.

[18]  L. Vécsei,et al.  The epidemiology of multiple sclerosis in Europe , 2006, European journal of neurology.

[19]  Hans Lassmann,et al.  Mitochondrial defects in acute multiple sclerosis lesions , 2008, Brain : a journal of neurology.

[20]  A. Thompson,et al.  Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. , 2008, Brain : a journal of neurology.

[21]  Anthony Feinstein,et al.  Adherence to interferon β-1a therapy using an electronic self-injector in multiple sclerosis: a multicentre, single-arm, observational, phase IV study , 2016, BMC Research Notes.

[22]  Ioannis Milonas,et al.  Axonal damage in multiple sclerosis: a complex issue in a complex disease , 2004, Clinical Neurology and Neurosurgery.

[23]  Howard L Zwibel,et al.  Improving quality of life in multiple sclerosis: an unmet need. , 2011, The American journal of managed care.

[24]  O Ciccarelli,et al.  The role of mitochondria in axonal degeneration and tissue repair in MS , 2012, Multiple sclerosis.

[25]  A. Thompson,et al.  Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis , 2005, The Lancet Neurology.

[26]  F. Collins,et al.  A new initiative on precision medicine. , 2015, The New England journal of medicine.

[27]  Aj Thompson,et al.  MSIF Atlas of MS database update: multiple sclerosis resources in the world 2013 , 2012 .

[28]  Kathleen Costello,et al.  Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. , 2008, Medscape journal of medicine.

[29]  B. Trapp,et al.  Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis , 2011, Progress in Neurobiology.

[30]  M.A.J. Visschedijk Evaluation of a psychosocial intervention program for patients with multiple sclerosis , 1999 .

[31]  S. Reingold,et al.  Defining the clinical course of multiple sclerosis , 1996, Neurology.

[32]  Neeta Garg,et al.  An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis , 2015, Brain and behavior.

[33]  David E Jones Early Relapsing Multiple Sclerosis , 2016, Continuum.

[34]  Bruce H Dobkin,et al.  The Promise of mHealth , 2011, Neurorehabilitation and neural repair.

[35]  Anastasius Gavras,et al.  Requirements Engineering for Digital Health , 2014 .

[36]  Patrick Vermersch,et al.  The patient's perspective: How to create awareness for improving access to care and treatment of MS patients? , 2016, Multiple sclerosis.

[37]  Marjorie Skubic,et al.  Exploring the feasibility and acceptability of sensor monitoring of gait and falls in the homes of persons with multiple sclerosis. , 2016, Gait & posture.

[38]  Gavin Giovannoni,et al.  The importance of a multi-disciplinary perspective and patient activation programmes in MS management , 2016, Multiple sclerosis.

[39]  Peter K Stys,et al.  Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis , 2009, The Lancet Neurology.